Search results
Showing 106 to 120 of 285 results for diarrhoea
Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
Self-expanding implant insertion into the intersphincteric space for faecal incontinence (IPG685)
Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.
View recommendations for IPG685Show all sections
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Percutaneous thoracic duct embolisation for persistent chyle leak (IPG755)
Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.
View recommendations for IPG755Show all sections
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.